Edwards Lifesciences Co. (NYSE:EW - Get Free Report) Director Michael A. Mussallem sold 29,350 shares of the firm's stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $84.77, for a total transaction of $2,487,999.50. Following the completion of the transaction, the director now directly owns 4,486 shares in the company, valued at approximately $380,278.22. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Edwards Lifesciences Stock Up 0.9 %
EW opened at $85.06 on Friday. The company has a 50 day moving average of $90.13 and a 200 day moving average of $79.23. The company has a market cap of $51.26 billion, a PE ratio of 36.66, a price-to-earnings-growth ratio of 3.55 and a beta of 1.10. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08.
Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. The company had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. On average, sell-side analysts expect that Edwards Lifesciences Co. will post 2.77 EPS for the current year.
Institutional Inflows and Outflows
Biden to Drop BOMBSHELL June 13th?
From Paradigm Press | Ad
Biden’s days are numbered!
According to a former CIA and Pentagon insider…
He’s about to drop out of the presidential race on June 13th!
Click here now to see his shocking evidence.
Large investors have recently bought and sold shares of the company. DSM Capital Partners LLC bought a new position in Edwards Lifesciences in the 4th quarter valued at $28,000. Turtle Creek Wealth Advisors LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth $34,000. Riverview Trust Co bought a new stake in shares of Edwards Lifesciences during the 1st quarter worth $34,000. Pingora Partners LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth $38,000. Finally, Operose Advisors LLC lifted its holdings in shares of Edwards Lifesciences by 247.0% during the 3rd quarter. Operose Advisors LLC now owns 635 shares of the medical research company's stock worth $44,000 after acquiring an additional 452 shares during the last quarter. 79.46% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Several brokerages recently weighed in on EW. Morgan Stanley raised their price target on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the company an "overweight" rating in a research report on Thursday, March 21st. Stifel Nicolaus increased their price objective on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the company a "hold" rating in a research note on Friday, April 26th. Evercore ISI decreased their price objective on shares of Edwards Lifesciences from $92.00 to $89.00 and set an "in-line" rating for the company in a research note on Friday, April 26th. Piper Sandler increased their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company a "neutral" rating in a research note on Friday, April 26th. Finally, Royal Bank of Canada increased their price objective on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an "outperform" rating in a research note on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $92.71.
Get Our Latest Report on Edwards Lifesciences
Edwards Lifesciences Company Profile
(
Get Free Report)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
